The NIAID funded UTMB Clinical Proteomics Center is a collaborative resource to identify predictive biomarker panels of outcome or therapeutic in humans with NIAID Category A-C agents or new/emerging infectious agents.
The CPC seeks to identify biomarkers that predict disease severity or vaccine response. Projects have been selected by peer review. The CPC uses a combination of 2 dimensional gel electrophoresis and mass spectrometry to identify putative biomarker panels. These panels of biomarkers are analyzed by our bioinformatics team to develop predictive models for verification in larger populations. These data and reagents are shared with our collaborators and jointly published to the scientific community.
Learn about the four essential process components — discovery, verification, assay development, and clinical validation. of the biomarker development pipeline
Explore our projects in:
Download and use our software developed for quantitative proteomics and mass spectral analysis under this contract.